Les Echos.fr - March 2, 2011
Ipsen recorded in 2010 net profit down 39.1% to 95.3 million euro due to the loss of value and the depreciation of certain drugs. Operating profit was 128.8 million, a loss of 25.3% over 2009. For 2011 the company French biotech expected to grow by 8% Sales of drugs Speciality Care and a decrease of 8-10% of those products Primary Care.
0 comments:
Post a Comment